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Introduction
Serum cortisol levels and blood pressure (BP) both have well-
documented circadian rhythms. Normally, cortisol levels peak in the 
early morning and drop to their lowest concentration at night [1,2]. The 
BP circadian rhythm is typically characterized by minor fluctuations 
throughout the day and night, with an overall dipping that occurs 
during the night. In normotensive subjects there is typically a 10% to 
20% reduction in BP during sleep [3-5]. Most studies that examine 
cortisol and BP rhythms tend to look at them in isolation, which could 
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Abstract
Patients on steroid replacement therapy are at an increased risk of cardiovascular complications owing to the fact 
that disruptions in the cortisol diurnal rhythm may affect the blood pressure (BP) profile.
Aim: To evaluate the circadian BP profiles of patients with secondary adrenal insufficiency (SAI) and congenital 
adrenal hyperplasia (CAH) on steroid replacement therapy and to compare BP profiles of patients receiving 
hydrocortisone (HC) in different dosing schedules.
Methods: The study included 33 patients: 15 SAI and 18 CAH (mean age 13.2 years 95CI 11.3-15.1). There were 
no patients with previously diagnosed overt hypertension. Patients with SAI received a mean of 7.39 mg/m2 of HC in 3 
daily doses (in the morning (M) 50%, in the afternoon (A) 25%, in the evening (E) 25%), CAH patients 17.9 mg/m2 of HC 
in the following dosing schedules: 5 patients in 3 equal doses, 7 patients received M: 40% A: 40% E: 20%, the remaining 
6 patients had the same dosing schedule as patients with SAI. Fludrocortisone (FC) was given to 13 patients with CAH 
in 2 equal daily doses. The total dose of HC/FC as well as the dosing schedule of HC was adjusted individually based 
on clinical and biochemical outcomes. Standard 24-hour BP monitoring (ABPM) was performed using an Ambulatory 
BP Monitor (Space labs 90217, USA).
Results: The majority of the patients (almost 70% SAI, 80% CAH) presented with an abnormal 24-hour BP profile. 
There were no significant differences in ABPM results between SAI and CAH patients, and no differences between 
CAH patients treated with and without FC. There was no correlation between HC and FC doses [mg/m2] and ABPM 
results except that mean night SBP values increased with greater HC doses (r=0.51, p<0.05). Among the CAH group 
the highest percentage of abnormal ABPM results was observed in patients who received HC in doses: M: 50% A: 25% 
and E: 25%, the most favorable BP profile was observed in patients with dosing schedule: M: 40%, A: 40%, E: 20%. 
However there were no significant differences between patients with different treatment protocols, the results suggest 
that observed disruptions of the BP profile could be related to the HC dosing schedule.
Conclusions: The incidence of abnormal BP profiles in patients on steroid replacement therapy due to SAI and 
CAH without overt hypertension is high. The disruptions of the BP profiles are not associated with the dose of HC or 
FC. The abnormal BP profiles in patients with SAI or CAH may be related to the HC dosing schedule. 24-hour ABPM 
seems to be a useful, non-invasive and safe method for the monitoring of HC and FC replacement therapy in patients 
with adrenal insufficiency. Further investigations in the larger groups of patients are needed.
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obscure the potential links between them. There are only a few studies 
that confirm an association between cortisol levels and BP fluctuations 
[2,6-9]. An elegant study performed by Holt-Lunstad and Steffen in 
302 healthy adult volunteers revealed that a decreased diurnal variation 
in cortisol levels was associated with a decreased diurnal variation in 
BP, whereas normal cortisol levels were a significant and independent 
predictor of normal BP dipping [2]. An abnormal BP circadian 
rhythm, and in particular a non- dipping phenomenon is associated 
with increased health risks including left ventricular hypertrophy 
[10-13], cerebrovascular stroke [14], cardiovascular morbidity [12], 
kidney damage [14], and increased mortality [15,16]. Thus, disrupted 
circadian cortisol and in consequence BP rhythms may have important 
long-term health implications. All patients with adrenal insufficiency 
on life-long hydrocortisone (HC) replacement therapy are at risk of 
both cortisol rhythm and BP profile disruption and their sequelae. 
Thus the HC supplementation regimen could be crucial. Under normal 
circumstances the secretion of cortisol and adrenal androgens is under 
the dominant control of pituitary ACTH. In contrast, aldosterone, 
which has a predominantly mineralocorticoid function, is primarily 
regulated by the renin-angiotensin system. It is also additionally 
influenced by sodium, potassium, dopamine, and serotonin levels [17]. 
Secondary adrenal insufficiency (SAI) (central hypoadrenalism) 
characterized by a deficit of ACTH is commonly found in patients 
with multihormonal pituitary deficiency (GH, TSH, LH, FSH, ADH) 
[17]. The most common cause of congenital adrenal hyperplasia 
(CAH) is 21-hydroxylase deficiency [18], which leads to a decrease in 
cortisol and aldosterone synthesis (in 75% of cases). Lack of cortisol 
leads to an increase in ACTH and stimulation of the adrenal cortex, 
with accumulation of cortisol precursors that are shunted to the sex 
hormone pathway [18]. 
The current treatment of SAI and CAH consists of the administration 
of glucocorticoids, and in the case of CAH mineralocorticoids as well 
(Fludrocortisone, FC) if necessary. The goal of treatment in both 
diseases is replacement of cortisol to prevent adrenal crisis, and to 
suppress the abnormal secretion of adrenal androgens in CAH [17,18]. 
Hydrocortisone (HC) is considered the drug of choice in these two 
cases. For the reason that modern techniques which measure cortisol 
production rates have suggested that the mean total daily production is 
10 mg/m2, that dose of HC is recommended [17,19,20]. In order for it 
to correlate with the circadian rhythm, the dose should be administered 
three times a day, usually 50% of the dose in the morning, 25% around 
lunchtime, and 25% in the early evening [17,20,21]. In order to initially 
decrease markedly elevated sex hormone levels in CAH patients during 
infancy, doses of up to 25 mg/m2 of HC may be required, however 
in growing children a typical dosing schedule is 10-15 mg/m2 three 
times a day. After achieving adult height, patients are often switched 
to longer-acting glucocorticoid preparations that can be given once 
or twice a day to maximize convenience and androgen synthesis 
inhibition. Some authors recommend using a reverse circadian pattern 
of HC replacement therapy to optimize androgen suppression, because 
glucocorticoid given before bedtime suppresses the ACTH night-time 
surge [22-24]. Others advocate giving the highest glucocorticoid dose in 
the morning or even waking the patient up at 3:00 am in an attempt to 
approximate the normal physiological timing of cortisol secretion [25-
28]. Nevertheless no current glucocorticoid therapy is able to mimic 
normal cortisol circadian rhythms, and in consequence BP rhythms 
which may contribute to suboptimal clinical outcomes. The patients 
on steroid replacement are undoubtedly at higher (in comparison 
to general population) risk of overt hypertension. Moreover, even 
if they present with normal results of the casual BP measurements, 
they may have disruptions of the circadian BP rhythm [2,7-9]. To 
date, investigators have failed to determine unequivocally what is the 
frequency of such disorders and what are the main determinants and 
risk factors [2,7-9].
The Aim of the Study 
 To evaluate daily BP profiles in patients with SAI and CAH on 
HC replacement therapy [1,2]. To compare BP profiles in patients with 
CAH treated with HC in three different dosing schedules.
Patients and Methods 
The studied group of this pilot study consisted of 33 patients with 
adrenal insufficiency, of which 15 had secondary adrenal insufficiency 
(8 girls and 7 boys) and 18 (11 girls and 7 boys) congenital adrenal 
hyperplasia due to 21 hydroxylase deficiency (the diagnosis was 
established based on the results of urinary steroid profile analysis using 
gas chromatography/mass spectrometry).
The mean age was 13.2 years with a confidence interval of 95CI 
(11.3-15.1). 
The exclusion criteria were: presence of previously diagnosed overt 
hypertension, anti-hypertensive treatment and other endocrinological 
disorders except secondary thyroid insufficiency and growth hormone 
deficiency on hormonal replacement therapy. 
In the group of patients with secondary adrenal insufficiency all 
were affected by multiple pituitary insufficiency, 12 had congenital 
defects of the pituitary gland and 3 acquired pituitary insufficiency due 
to pituitary tumors. 
There were no significant differences with regard to age and 
auxological parameters (Table 1). 
The daily hydrocortisone dose was significantly higher in the CAH 
group (13 patients were also treated with FC). In all patients with SAI, 
hydrocortisone was administered in 3 daily doses: 50% of the daily dose 
was given in the morning (M), 25% in the afternoon (A) and 25% in 
the evening (E). In the CAH group, 5 patients received hydrocortisone 
in 3 equal doses, 7 received: M: 40%, A: 40%, E: 20%, 6 patients had 
a dosing schedule similar the one in patients with SAI (M: 50%, A: 
25%, E: 25%). The total dose of HC as well as the dosing schedule was 
adjusted individually based on clinical and biochemical outcomes 
Parameters Secondary adrenal insufficiency mean [95% CI] Congenital adrenal hyperplasia mean [95% CI] p
N 15 18 -
Age [years] 13.2 [11.3-15.1] 11 [9.2-12.7] 0.07
Height [SDS] -0.49 [-1.25-0.26] -0.52 [-1.3-0.25] 0.79
BMI [SDS] 0.04 [-0.5-0.6] 0.21[-0.4-0.8] 0.61
Hydrocortisone  daily dose mg/m2 7.39[6.1-8.6] 17.9[15.4-20.3] 0.002
Fludrocortisone daily dose mg/m2 - 0.03[0.01-0.04] -
Table 1: Characteristics of the studied groups: secondary adrenal insufficiency (SAI) and congenital adrenal hyperplasia (CAH).
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such as: growth velocity, body weight, bone age, blood pressure, 
17-hydroxyprogesteron levels in the blood and 17-ketosteroid levels in 
the urine. Fludrocortisone (FC) was given in 2 daily doses, the total 
dose was adjusted based on plasma renin activity and BP. 
Body weight and height were measured to the nearest 0.1 kg and 
0.1 cm, respectively, using a stadiometer (Harpenden, UK) and a 
balanced scale. As the standard of reference normal values from the 
local population were used [29]. 
24-hour BP monitoring was performed using an Ambulatory BP 
Monitor (Space labs 90217, USA), with a cuff which was the same 
size as the one used to measure casual blood pressure. It was set to 
take a reading every 15 minutes (day 6 a.m.-10:59 p.m.), and every 30 
minutes (night 11:00 p.m.-5:59 a.m.). The monitoring was performed 
in a standard setting, patients went to sleep at 9-10 p.m. and got up 
at 6-7 a.m. Sleep and wake periods were established based on a diary 
completed by the child’s parents. Recordings with at least 70% valid 
readings and at least one reading every hour were considered for the 
analysis. The following parameters were analyzed: mean 24-h systolic 
(SBP), diastolic (DBP), and mean arterial pressure (MAP), mean 
day-time systolic (dSBP), diastolic (dDBP), and MAP (dMAP), mean 
night-time systolic (nSBP), diastolic (nDBP), and MAP (nMAP). Blood 
pressure load was calculated separately for the awake and asleep periods. 
BP load was defined as the percentage of valid BP measurements above 
a set threshold (95th percentile for sex and the height) value [4,5]. Loads 
in excess of 30% were considered elevated. Loads in excess of 50% were 
considered severely elevated. The calculation of nocturnal dipping 
was based on a formula by the American Heart Association: [(dSBP–
nSBP)/dSBP] × 100. Normal dipping was defined as a ≥10% decline in 
BP [3,5]. 
In order to compare the two groups the two-sided Mann-Whitney 
U-test and ANOVA tests were used. Spearman ρ was used to measure 
the strength of association between pairs of variables. The level of 
significance was set at p<0.05. Calculations were performed using the 
STATISTICA 10.0 PL soft ware (Poland).
Results
The majority of the patients presented with abnormal 24-hour BP 
profile: almost 70% with SAI 80% with CAH. The patients with normal 
BP profiles were significantly younger in comparison to individuals 
with BP profile abnormalities (mean 9.6 vs. 12.8 years). 
There were no significant differences in ABPM results between 
SAI and CAH patients. The mean values of the 24h SBP, day time SBP 
and night time SBP were slightly higher in the CAH group, however 
the differences were not significant (SBP: 108.8 vs. 112.2 mmHg, 
dSBP: 111.7 vs. 114.2 mmHg, nSBP: 100.6 vs. 105.2 mmHg in SAI and 
CAH groups respectively). The mean 24-hour SBP loads were also 
comparable: an elevated SBP load was observed in 20% of patients with 
SAI and in 17% of CAH patients (in 6% of CAH patients elevation was 
severe). Day time SBP load was elevated in 20% of SAI and 12% of 
CAH patients (severely elevated in 6% CAH patients). Interestingly, 
the night time SBP seems to be more affected in CAH group since the 
night time SBP load was elevated in 26% (13% seriously elevated) of 
SAI, and 34% (28 seriously elevated) of CAH patients. 
There were also no significant differences among 24h DBP, day 
time DBP and night time DBP mean values between SAI and CAH 
patients (66.5 vs. 67.2 mmHg, 69.7 vs. 69.3 mmHg, 56.6 vs. 59.5 mmHg 
respectively). An elevated 24-h DBP load was observed in 13% of SAI 
and in 11% of CAH patients. 27% of SAI patients presented an elevated 
day time DBP load (severely elevated in 7%), but interestingly it was 
not observed in any patient with CAH. Night time DBP load elevation 
was present in 27% of SAI patients (severely elevated in 7%), and in 
23% of CAH patients (severely elevated in 17%). 
The mean values of the 24h MAP, day time MAP and night time 
MAP were comparable in both groups: 24h MAP 81.5 vs. 82.8 mmHg, 
dMAP 84 vs. 84.6 mmHg, nMAP 71.5 vs. 75.8 mmHg in SAI and CAH 
patients respectively.
In 21 patients 8 (53%) with SAI and 13 (72%) with CAH (of 
which 11 patients were on FC) there was no significant night time dip. 
Nevertheless there was no significant difference in the mean value of 
the nighttime dip between SAI and CAH patients (9.91 vs. 7.88%). 
There were no significant differences in ABPM results between CAH 
patients treated with or without FC (Table 2).
There was no correlation between HC and FC doses [mg/m2] and 
24 hour ABPM results except that mean night SBP values increased 
with greater HC doses (r=0.51, p<0.05). 
Among the CAH group the highest percentage of abnormal ABPM 
results was observed in patients who received HC in doses: M: 50% A: 
25% and E: 25%, the most favorable BP profile was observed in patients 
with dosing schedule: M: 40%, A: 40%, E: 20% (Table 3). However 
there were no significant differences between patients with different 
treatment protocols, the results suggest that observed disruptions of 
the BP profile could be related to the HC dosing schedule.
Discussion
The circadian rhythm of blood pressure is maintained within 
normal limits through the interplay of various mechanisms including 
the secretion of cortisol and aldosterone [1,2]. Unfortunately when 
these hormones are exogenously administered they are not under 
the regulatory feedback mechanisms that maintain BP homeostasis. 
The results of the present study show that long term HC and/or 
FC replacement therapy do not seem to be associated with overt 
hypertension in young people with SAI or CAH when using casual 
BP references. This observation is in agreement with previously 
published data [7]. Even though no single case of overt hypertension 
was noted, almost 70% of SAI and 80% of CAH patients presented with 
Table 2: Outcome variables in patients with CAH with and without fludrocortisone 
replacement therapy.
Fludrocortisone no fludrocortisone p
HC dose [mg/m2] 17.7 18.3 0.55
mean 24h SBP (mmHg) 111.1 115.2 0.3
mean 24h DBP (mmHg) 65.8 70.8 0.1
mean 24h MAP (mmHg) 81.6 85.8 0.27
mean dSBP (mmHg) 113.1 117.4 0.12
mean dDBP (mmHg) 68 72.8 0.13
mean dMAP (mmHg) 83.6 87.4 0.13
mean nSBP (mmHg) 105 106 0.8
mean nDBP (mmHg) 58.3 62.6 0.2
mean nMAP (mmHg) 75 77.8 0.3
24h SBP load (%) 14.3 19.7 0.4
dSBP load (%) 12 16.9 0.3
nSBP load (%) 22 27.1 0.9
24h DBP load (%) 10.7 17.8 0.1
dDBP load (%) 9.5 13.9 0.2
nDBP load (%) 15.4 31 0.1
night time dip (%) 7.1 9.6 0.5
Citation: Wojcik M, Janus D, Poplawska K, Tyrawa K, Zygmunt-Gorska A, et al. (2013) High Incidence of Abnormal Circadian Blood Pressure Profiles 
in Patients on Steroid Replacement Therapy due to Secondary Adrenal Insufficiency and Congenital Adrenal Hyperplasia without Overt 
Hypertension - Initial Results. J Steroids Hormon Sci S12: 005. doi:10.4172/2157-7536.S12-005
Page 4 of 5
J Steroids Hormon Sci Steroid Hormone Metabolism        ISSN: 2157-7536 JSHS, an open access journal 
an abnormal 24-hour BP profile. The results of the study shows, those 
casual, ambulatory BP measurements are not a sufficient tool for the 
monitoring of long-term cardiovascular risk factors in such patients, 
because adrenocortical insufficiency and subsequent replacement 
therapy are not usually associated with overt hypertension, but have 
often been shown to account for a loss of circadian blood pressure 
rhythm. Due to the fact that cortisol and BP circadian rhythms are 
closely linked, 24-hour BP monitoring may be a useful additional tool 
for the non-invasive monitoring of replacement therapy. 
Our results show that the total daily dose of HC was not associated 
with 24-hour BP profile parameters, except mean night time SBP. The 
lack of such an association was also showed in the study performed by 
Ubertini et al. [8]. Our results also show that there was no significant 
impact of the FC, since there were no significant differences between 
patients with CAH receiving only HC and combined HC + FC therapy. 
However in the group of patients receiving FC the incidence of 
decreased night time dip was higher compared to the group receiving 
HC alone, but there were no significant difference in the mean values of 
night time dip between these two groups. Interestingly, decreased night 
time dip was also observed in the majority (53%) of patients with SAI. 
A more important factor which can modulate the circadian variation 
of BP might be the regimen of HC administration. Only a few studies 
have been dedicated to the analysis of the relationship between the HC 
administration model and BP profiles in such groups of patients [6,9]. 
In these studies the administration of a higher morning dose of HC 
was associated with a more physiologic BP rhythm and preservation 
of night time dipping. The authors suggested that patients with SAI on 
HC replacement therapy could maintain an approximately normal BP 
rhythm. This has not been confirmed in the present study. Only 46% of 
SAI patients presented night time dip ≥10%. The problem is even more 
complicated in patients with CAH. A few recent studies, investigating 
BP profiles in CAH patients, have reported conflicting results. Even 
though Ubertini et al. showed no significant differences between CAH 
patients and the general population concerning BP profiles [8], other 
authors indicated a higher prevalence of abnormalities, especially a 
decrease in night time dip in these patients [30,31]. One study with 
11 CAH participants showed that a more physiological administration 
of HC with a higher morning dose was associated with a more 
physiological BP profile, with greater night time dip, and not associated 
with poor biochemical parameters of control of the disease [6]. 
Our results show that the risk of an abnormal BP profile is present 
in as many as 80% of CAH patients, irrespective of HC replacement 
schedule and additional treatment with FC. Nevertheless the most 
favorable profile was observed in patients receiving 40% of their daily 
dose in the morning, 40% in the afternoon and 20% in the evening. 
This novel observation needs further examination in larger groups of 
patients. 
Conclusions
The incidence of abnormal BP profiles in patients on steroid 
replacement therapy due to SAI and CAH without overt hypertension 
is high. The disruptions of the BP profiles are not associated with the 
dose of HC neither with FC treatment (in CAH patients). The abnormal 
BP profiles in patients with SAI or CAH might be related to the HC 
dosing schedule. 24-hour ABPM seems to be a useful, non-invasive and 
safe method for the monitoring of HC and FC replacement therapy in 
patients with adrenal insufficiency. Further investigations in the larger 
groups of patients are needed.
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